Topics

Pfizer pays $250 million upfront as part of deal to develop Akcea's antisense therapy AKCEA-ANGPTL3-LRx https://www.firstwordpharma.com/node/1672053  $PFE $AKCA $IONS

08:04 EDT 7 Oct 2019 | FirstWord Pharma

Pfizer pays $250 million upfront as part of deal to develop Akcea's antisense therapy AKCEA-ANGPTL3-LRx https://www.firstwordpharma.com/node/1672053 

Original Article: Pfizer pays $250 million upfront as part of deal to develop Akcea's antisense therapy AKCEA-ANGPTL3-LRx https://www.firstwordpharma.com/node/1672053  $PFE $AKCA $IONS

NEXT ARTICLE

More From BioPortfolio on "Pfizer pays $250 million upfront as part of deal to develop Akcea's antisense therapy AKCEA-ANGPTL3-LRx https://www.firstwordpharma.com/node/1672053  $PFE $AKCA $IONS"

Quick Search

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Antisense therapy
Most human diseases are caused by production of abnormal proteins or malfunctioning proteins.   Antisense therapy involves inhibiting production of these proteins.  When a gene is known to cause a specific disease and the genetic sequence ...